American Society of Hematology (ASH)
Refine Search
Biotechnology
US biotech major Gilead Sciences’ Kite subsidiary today announced strong four-year follow-up data from the pivotal ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL). 5 December 2020
Biotechnology
US biotech Incyte today announced detailed results from the pivotal Phase III REACH3 study that demonstrate Jakafi (ruxolitinib) significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GVHD) compared to best available therapy (BAT). 5 December 2020
Pharmaceutical
At least one aspect of 2020 will be the same as any other year – pharma companies will end it with the traditional major data dump at the American Society of Hematology (ASH) Meeting and Exposition. 26 November 2020
Pharmaceutical
At the annual meeting of the American Society of Hematology (ASH), French drugmaker Sanofi presented positive data for ex-Bioverativ asset sutimlimab. 11 December 2019
Pharmaceutical
At the 2019 ASH annual meeting, Bristol-Myers Squibb has announced positive results from the QUAZAR AML-001 study of an experimental oral hypomethylating agent, CC-486. 10 December 2019
Biotechnology
US pharma major Bristol-Myers Squibb presented data from multiple studies evaluating Reblozyl (luspatercept-aamt) in patients with anemia associated with multiple serious blood diseases at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. 10 December 2019
Pharmaceutical
Shares of US biotech firm ArQule spiked 102% to $19.60 in Monday pre-market trading, after it was revealed that it has received a takeover offer from US pharma giant Merck & Co. 9 December 2019
Biotechnology
US pharma major Bristol-Myers Squibb announced over the weekend that its Phase I study of lisocabtagene maraleucel (liso-cel) met its primary and secondary endpoints while demonstrating durable responses. 9 December 2019
Biotechnology
US biotech bluebird bio has presented new data from its Phase I/II HGB-206 study of its LentiGlobin gene therapy for sickle cell disease (SCD) at ASH. 9 December 2019
Biotechnology
Genomic medicine company Sangamo Therapeutics and its pharma partner Pfizer have announced updated follow-up results from the Phase I/II Alta study on the SB-525 gene therapy in patients with severe hemophilia A. 9 December 2019
Pharmaceutical
British pharma major AstraZeneca has presented interim Phase III data from the ELEVATE TN study of Calquence (acalabrutinib), at the 2019 American Society of Hematology (ASH) annual meeting. 9 December 2019
Biotechnology
At this year’s annual meeting of the American Society of Hematology (ASH), Johnson & Johnson has impressed with the first clinical data from its anti-BCMA CAR-T program, as rival candidates jostle for the lead in this area of innovation. 9 December 2019
Biotechnology
Swedish Orphan Biovitrum and Novimmune have presented positive data from a pivotal Phase II/III study of Gamifant (emapalumab-lzsg) at the annual meeting of the American Society of Hematology. 5 December 2018
Pharmaceutical
Janssen Pharmaceutical, the pharma business of US healthcare company Johnson & Johnson, has announced positive Phase III data for Darzalex (daratumumab) at the annual meeting of the American Society of Hematology. 5 December 2018
Biotechnology
Swiss pharma giant Roche has presented data from the largest pivotal study to date in children with hemophilia A at the American Society of Hematology Annual Meeting. 4 December 2018
Biotechnology
BeiGene clinical data from the pivotal Phase II trial of its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin’s lymphoma (cHL), at the Annual Meeting of the American Society of Hematology (ASH) yesterday. 4 December 2018
Pharmaceutical
Daiichi Sankyo yesterday announced positive comprehensive analyses of overall survival from the pivotal QuANTUM-R Phase III study of single agent quizartinib compared to salvage chemotherapy in patients with FLT3-ITD acute myeloid leukemia (AML). 4 December 2018
Pharmaceutical
Basel, Switzerland-based Roche has announced new Phase III data for Venclyxto (venetoclax) at the annual meeting of the American Society of Hematology. 4 December 2018
Pharmaceutical
AstraZeneca and its hematology subsidiary Acerta Pharma have presented new, long-term follow-up results for Calquence (acalabrutinib) at the annual meeting of the American Society of Hematology. 4 December 2018
Pharmaceutical
Takeda Pharmaceutical has presented positive results from the Phase III TOURMALINE-MM3 study of Ninlaro (ixazomib) at the annual meeting of the American Society of Hematology (ASH). 3 December 2018
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Biotechnology
Johnson & Johnson unit Janssen has presented the first data from the Phase III PERSEUS study at the annual meeting of the American Society of Hematology (ASH). 13 December 2023
Biotechnology
Kite, a subsidiary of US biotech major Gilead Sciences, has announced the results of new analyses supporting the use of Tecartus (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukaemia (R/R B-ALL). 12 December 2023
Biotechnology
At the 65th American Society of Hematology (ASH) annual meeting, Gilead Sciences company Kite announced results from a three-year follow-up analysis of the ZUMA-12 trial. 12 December 2023
Pharmaceutical
US pharma major Bristol Myers Squibb has announced the results of two early studies evaluating combinations of CELMoD agent golcadomide in non-Hodgkin lymphomas. 12 December 2023
Biotechnology
Australian biotech CSL Limited has announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of Hemgenix (etranacogene dezaparvovec-drlb) following a one-time infusion in people living with hemophilia B. 12 December 2023
Biotechnology
The Johnson & Johnson subsidiary Janssen has presented new long-term follow-up data at the 2023 American Society of Hematology (ASH) Annual Meeting from the Phase III GLOW and Phase II CAPTIVATE studies of first-line, fixed-duration treatment with Imbruvica (ibrutinib) plus AbbVie’s enclexta (venetoclax). 11 December 2023
Pharmaceutical
Swiss pharm giant Novartis has announced positive results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta (iptacopan). 11 December 2023
Biotechnology
Swiss pharma giant Roche has presented new data from its CD20xCD3 T-cell engaging bispecific antibody program at the 65th American Society of Hematology (ASH) Annual Meeting. 11 December 2023
Biotechnology
Adding Sarclisa (isatuximab) to carfilzomib, lenalidomide and dexamethasone (KRd) caused a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly-diagnosed multiple myeloma (MM). 11 December 2023
Biotechnology
New Jersey, USA-based cancer giant Bristol Myers Squibb has announced positive primary analysis results from the TRANSCEND FL study. 11 December 2023
Pharmaceutical
Britain’s largest drugmaker, AstraZeneca, has announced positive long-term results from the Phase III ALPHA trial at the annual meeting of the American Society of Hematology (ASH). 11 December 2023
Biotechnology
US pharma major Bristol Myers Squibb has presented updated results from the primary analysis of the Phase III COMMANDS trial at the 2023 American Society of Hematology (ASH) Annual Meeting. 10 December 2023
Biotechnology
Findings from the pivotal Phase III BASIS clinical trial evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) were released at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. 10 December 2023
Biotechnology
At this year’s American Society of Hematology (ASH) Annual Meeting, Swiss pharma giant Roche announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra (emicizumab) in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors. 10 December 2023
Biotechnology
With the end of the year approaching, it is again time for The American Society of Hematology (ASH) Annual Meeting, the last major pharmaceutical conference in the calendar. 9 December 2023
Pharmaceutical
As the 64th annual meeting of the American Society of Hematology (ASH) drew to a close in New Orleans on Tuesday, more clinical updates provided a window into the development prospects for two important programs in this therapy area. 14 December 2022
Biotechnology
US biotech major Regeneron added to its offering at this year’s American Society of Hematology (ASH) meeting with data on linvoseltamab in multiple myeloma. 13 December 2022
Pharmaceutical
Eli Lilly’s (NYSE: LLY) oncology company, Loxo@Lilly, has announced updated clinical data from the global Phase I/II BRUIN trial of pirtobrutinib. 13 December 2022
Biotechnology
USA-based Regeneron Pharmaceuticals has announced positive new and updated data from the Phase I ELM-1 and pivotal Phase II ELM-2 trials of its lymphoma candidate odronextamab. 12 December 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze